dose escalation study

Related by string. Dose Escalation Study * Doses . DOSE . DO Se . DOSES : mg kg dose . tolerated dose MTD . multiple ascending dose . priming doses / escalations . Escalation . Escalations . ESCALATION : label dose escalation . dose escalation trial . dose escalation . dose escalation clinical / studying . Studying . STUDY . studys : Pre Feasibility Study . Case Study . Study Shows . Study Reveals * *

Related by context. Frequent words. (Click for all words.) 75 Phase Ib 74 Phase 1b 71 placebo controlled 71 Phase 2b study 70 dose escalation 70 Phase 2a clinical 70 Phase 2a 69 double blind placebo 69 randomized placebo controlled 68 Phase IIa clinical 68 Phase IIa 68 Phase 2b clinical 68 Phase IIb clinical 68 multicenter 68 blind randomized placebo 68 Phase III clinical 68 pivotal Phase III 67 Phase IIb trial 67 clinical trial 66 Phase IIb 66 randomized double 66 randomized Phase 65 randomized controlled 65 safety tolerability 65 blind placebo controlled 65 pivotal Phase 65 pharmacokinetic 65 randomized 64 Phase III 64 tolerability 64 Phase 2b 64 pharmacokinetics 63 prospective randomized 63 pharmacodynamics 63 blind randomized 63 randomized clinical 62 Phase III clinical trials 62 Phase II 62 RG# [001] 62 IMGN# 61 evaluable patients 61 pharmacokinetic profile 61 RDEA# 61 multicenter study 60 docetaxel 59 dosing regimens 59 investigational compound 59 immunogenicity 59 gemcitabine 59 Phase 58 IDX# 58 Phase III trials 58 initiate Phase 57 AP# [003] 57 perifosine 57 sunitinib 57 clinical trials 57 dose regimen 57 mg dose 57 XL# [003] 57 CYT# 56 randomized controlled trial 56 relapsing remitting multiple sclerosis 56 MGCD# [002] 56 preclinical studies 56 Clinical Study 56 temozolomide 56 non inferiority 55 carfilzomib 55 antiviral activity 55 antitumor activity 55 investigational drug 55 T DM1 55 mg/m2 55 pharmacodynamic 55 INCB# [002] 55 monotherapy 55 humanized monoclonal antibody 55 AEZS 55 CK # 55 FTY# 55 tolerability profile 55 bavituximab 54 PRX # 54 solid tumors 54 evaluable 54 ACTEMRA 54 daclizumab 54 cytarabine 54 TMC# [001] 54 oral formulation 54 investigational 54 ANA# 53 Clinical Trial 53 prospective cohort 53 PMX # 53 pegylated interferon 53 primary endpoint 53 Preclinical studies 53 NSCLC 53 hormone refractory prostate cancer

Back to home page